Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03229200 · ClinicalTrials.gov registry record · Phase 4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
A Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin, sponsored by Pharmacyclics Switzerland.
- Active
- Registry status
- Phase 4
- Development phase
- 297
- Enrollment target
- 20
- Study locations
NCT03229200: Active Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin, sponsored by Pharmacyclics Switzerland.
NCT03229200 is a Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Pharmacyclics Switzerland. The registered enrollment target is 297 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03229200, a Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Pharmacyclics Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 297 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Primary Outcome
Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0.
Conditions Studied
Interventions
- DRUG Ibrutinib
Study Locations (20)
California
- Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center - Burbank
- City Of Hope National Medical Center - Duarte
- UCSD Moores Cancer Center - La Jolla
- University of California Los Angeles (UCLA) - Los Angeles
- Stanford University - Stanford
New York
- Northwell Health - New Hyde Park
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College-New York Presbyterian Hospital - New York
- University of Rochester - Rochester
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
North Carolina
- Levine Cancer Institute - Charlotte
- Southeastern Medical Oncology Center - Goldsboro
Georgia
- Emory University - Atlanta
Kentucky
- Norton Medical Plaza II, 3991 Dutchmans Lane - Louisville
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2027-05-10 |
| Phase | Phase 4 |
What the registry record for NCT03229200 still lists
NCT03229200 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (35% higher).
The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Ibrutinib is the first listed.
NCT03229200 names 20 study sites across 11 states, led by California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT03229200 about?
NCT03229200 is a clinical study titled "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.". Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their regio...
What is the current status of trial NCT03229200?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 297 participants. The study started on 2017-05-22. Estimated completion is 2027-05-10.
What conditions does trial NCT03229200 study?
This clinical trial studies the following conditions: Solid Tumor, Lymphoma, Non-Hodgkin, Graft Vs Host Disease, Lymphoma, B-Cell, Leukemia, B-cell.
What interventions are being tested in trial NCT03229200?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03229200?
This trial is sponsored by Pharmacyclics Switzerland, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03229200 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03229200's enrollment target sits among peer trials
297 22nd of 196 higher than 175 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Durvalumab Long-Term Safety and Efficacy Study
COMPLETED · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI